Industry Presentations
LUGPA Crossfire Series - mHSPC
Presentations
Optimizing Decision Making for Patients with mHSPC: Case-Based Review of Doublets vs Triplets
Speakers: Neal D. Shore, MD, FACSPaul R. Sieber, MD, President and Medical Director of ResearchElisabeth Heath, MD FACP, Associate Center Director, Translational Sciences Duration: 60 minutes
Presented on: October 31, 2023
*This session is not eligible for AMA PRA Category 1 CreditsTM
Moving Beyond ADT Alone: The Rationale for Early Intensification in mHSPC
Speakers: Neal D. Shore, MD, FACSBenjamin Lowentritt, MD, FACS, Vice president of Physician Services Duration: 60 minutes
Presented on: July 19, 2023
*This session is not eligible for AMA PRA Category 1 CreditsTM
The Evolution of the Modern Care Team with New mHSPC Treatment Options
Speakers: Neal D. Shore, MD, FACSMatthew R. Smith, MD, PhD, Professor of MedicineDavid Morris, MD, FACS, President, Co-Director Duration: 60 minutes
Presented on: February 23, 2023
*This session is not eligible for AMA PRA Category 1 CreditsTM
Speakers
Neal D. Shore, MD, FACS
Neal D. Shore, MD, FACS
Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina.
Dr. Shore has conducted more than 350 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Bladder Cancer Advocacy Network, and is Immediate Past President, Large Urology Group Practice Association. He is a founder for both: CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee and the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE(Academic Editor), Urology Practice, World Journal of Urology, and serves as Editor, Everyday Urology-Oncology. He has more than 175 peer reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, New England Journal of Medicine, European Urology, Journal Urology, Urology, BJUI, PCPD, and numerous other high impact scientific journals.
A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6-month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.Session Appearances
Moving Beyond ADT Alone: The Rationale for Early Intensification in mHSPC
The Evolution of the Modern Care Team with New mHSPC Treatment Options
Kidney-Sparing Approaches in UTUC: A Risk-Based Approach to Care
Optimizing Decision Making for Patients with mHSPC: Case-Based Review of Doublets vs Triplets
Paul R. Sieber, MD
Paul R. Sieber, MD
President and Medical Director of Research
Paul R. Sieber, MD, is a practicing urologist based in Lancaster, Pennsylvania, and currently serves as president and the medical director of research for Lancaster Urology. Dr Sieber, who focuses primarily on prostate cancer, serves as the principal investigator for all of the clinical trials at Lancaster Urology. Having served as a principal investigator in more than 200 trials, he is enthusiastic about clinical trials and research as he looks at what can benefit his patients in the future. Dr Sieber earned his medical degree from the Indiana University-Purdue University at Indianapolis.Elisabeth Heath, MD FACP
Elisabeth Heath, MD FACP
Associate Center Director, Translational Sciences
Benjamin Lowentritt, MD, FACS
Benjamin Lowentritt, MD, FACS
Vice president of Physician Services
Benjamin Lowentritt, MD, FACS, serves as vice president of Physician Services and director of Prostate Cancer Services for United Urology Group in Baltimore, Maryland. He also serves as the medical director of the Comprehensive Prostate Cancer Care Program at Chesapeake Urology. Dr Lowentritt has been at the forefront of robotic urology procedures and was the first surgeon in Maryland to perform robot assisted surgery for bladder cancer. He has authored articles on a variety of urologic topics. Dr Lowentritt has served as past president of the Mid-Atlantic Section of the American Urological Association. He serves on the board of directors for MedChi and the Maryland State Medical. Dr Lowentritt has been recognized as a Top Doctor in multiple publications.Matthew R. Smith, MD, PhD
Matthew R. Smith, MD, PhD
Professor of Medicine
David Morris, MD, FACS
David Morris, MD, FACS
President, Co-Director